Smart devices and apps have been targeting health care for years, and US FDA has been making a big push to build a framework and expertise to regulate the space. Those two lines of effort met in a big way last quarter, with the first set of high-profile direct-to-consumer mobile apps cleared by FDA.
The Apple Watch apps intended to monitor for atrial fibrillation gained FDA go-ahead in September. (Also see "FDA's Speedy Apple Watch De Novos Raise Questions For Industry" - Medtech...
Global Look
Also check out a snapshot of Q3 approvals outside the US: Q3 Global Device Approvals: Another Big Quarter For Coronary And Peripheral Intervention Approvals
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?